ArticlemAbs2018

Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.

Xiaoying Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.